Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat

Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat

Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.

Moderna Stock Falls as Citi Says $200 Needs $26B in Cancer Sales

Moderna Inc. (NASDAQ: MRNA) shares fell 8.57% to $186.03 in Wednesday premarket trading after Citi downgraded the stock.Visit Website

Moderna Shares Slump As Citi Downgrades To 'Sell’ After Cancer Vaccine Rally

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.

Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.

Moderna has been on a tear since mid-August. Citi now sees it plunging 60%

Analyst Geoff Meacham downgraded the biotech name to sell.

Citi Downgrades Moderna (MRNA) Stock to Sell After 222% Rally

Citi downgrades Moderna (MRNA) to Sell with $80 target, citing valuation concerns after 222% rally. Stock falls 5.7% on bearish call from analyst.